SPOTLIGHT -
Dr. Brown on the Benefits of Minimally Invasive Surgery in Ovarian Cancer
Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.
Read More
Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas
Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.
Dr. Brown on the Utility of PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer
Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.
Dr. Brown on the Clinical Implications of the PRIMA Trial in Ovarian Cancer
Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.
Dr. Brown on Future Directions for Surgery in Ovarian Cancer
Jubilee Brown, MD, discusses future directions for surgery in ovarian cancer.
Dr. Brown on the Utility of Minimally Invasive Surgery in Ovarian Cancer
Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.
Dr. Brown on Germline and Somatic Testing in Ovarian Cancer
Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.
Dr. Brown on the Importance of Genetic Testing in Ovarian Cancer
Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.
Dr. Brown on the Adoption of Genetic Testing
Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the adoption of genetic testing into routine clinical practice.
Dr. Brown on Genetic Counseling for Breast and Ovarian Cancer
Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)